stocks logo

RCUS

Arcus Biosciences Inc
$
10.230
+0.36(3.647%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
10.240
Open
9.880
VWAP
10.11
Vol
713.70K
Mkt Cap
1.08B
Low
9.610
Amount
7.21M
EV/EBITDA(TTM)
--
Total Shares
90.95M
EV
134.20M
EV/OCF(TTM)
--
P/S(TTM)
6.76
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
34.78M
-3.4%
-1.210
+17.51%
32.48M
-32.33%
-1.182
+18.23%
32.86M
-15.75%
-1.165
+14.25%
Estimates Revision
The market is revising Downward the revenue expectations for Arcus Biosciences, Inc. (RCUS) for FY2025, with the revenue forecasts being adjusted by -16.8% over the past three months. During the same period, the stock price has changed by 24.00%.
Revenue Estimates for FY2025
Revise Downward
down Image
-16.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+19.48%
In Past 3 Month
Stock Price
Go Up
up Image
+24.00%
In Past 3 Month
9 Analyst Rating
up Image
147.21% Upside
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 25.29 USD with a low forecast of 12.00 USD and a high forecast of 46.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
1 Hold
0 Sell
Strong Buy
up Image
147.21% Upside
Current: 10.230
sliders
Low
12.00
Averages
25.29
High
46.00
Barclays
Peter Lawson
Buy
Maintains
$29 → $14
2025-04-23
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
to
Strong Buy
Upgrades
$24
2025-02-26
Reason
B of A Securities
Jason Zemansky
Hold
Maintains
$22 → $17
2025-02-19
Reason
Morgan Stanley
Terence Flynn
Buy
Maintains
$36 → $25
2025-02-18
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Maintains
$20 → $18
2025-02-18
Reason
HC Wainwright & Co.
Emily Bodnar
Hold
Reiterates
$20
2024-11-06
Reason

Valuation Metrics

The current forward P/E ratio for Arcus Biosciences Inc (RCUS.N) is -2.25, compared to its 5-year average forward P/E of -6.27. For a more detailed relative valuation and DCF analysis to assess Arcus Biosciences Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.27
Current PE
-2.25
Overvalued PE
-1.62
Undervalued PE
-10.93

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.29
Current EV/EBITDA
-0.26
Overvalued EV/EBITDA
0.57
Undervalued EV/EBITDA
-9.16

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
15.74
Current PS
6.95
Overvalued PS
25.63
Undervalued PS
5.85

Financials

Annual
Quarterly
FY2025Q1
YoY :
-80.69%
28.00M
Total Revenue
FY2025Q1
YoY :
-3150.00%
-122.00M
Operating Profit
FY2025Q1
YoY :
+2700.00%
-112.00M
Net Income after Tax
FY2025Q1
YoY :
+2180.00%
-1.14
EPS - Diluted
FY2025Q1
YoY :
+2116.67%
-133.00M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+14392.75%
-400.00
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
20.3K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
3
15.4M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 186.42% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
87.5K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
6.9M
Volume
Months
6-9
2
2.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RCUS News & Events

Events Timeline

2025-07-10 (ET)
2025-07-10
08:34:20
Arcus Biosciences quemliclustat granted orphan drug designation by FDA
select
2025-06-30 (ET)
2025-06-30
21:19:46
Arcus Biosciences treatment of pancreatic cancer granted orphan designation
select
link
2025-06-01 (ET)
2025-06-01
16:11:54
Arcus Biosciences presented data for casdatifan plus cabozantinib
select
Sign Up For More Events

News

5.0
07-24Newsfilter
Arcus Biosciences Announces New Employment Inducement Grants
9.0
07-10NASDAQ.COM
Arcus Biosciences' Quemliclustat Gets Orphan Drug Status For Pancreatic Cancer
9.0
07-10SeekingAlpha
Arcus says Gilead-partnered cancer drug won FDA orphan status
Sign Up For More News

FAQ

arrow icon

What is Arcus Biosciences Inc (RCUS) stock price today?

The current price of RCUS is 10.23 USD — it has increased 3.65 % in the last trading day.

arrow icon

What is Arcus Biosciences Inc (RCUS)'s business?

arrow icon

What is the price predicton of RCUS Stock?

arrow icon

What is Arcus Biosciences Inc (RCUS)'s revenue for the last quarter?

arrow icon

What is Arcus Biosciences Inc (RCUS)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Arcus Biosciences Inc (RCUS)'s fundamentals?

arrow icon

How many employees does Arcus Biosciences Inc (RCUS). have?

arrow icon

What is Arcus Biosciences Inc (RCUS) market cap?